Q-PAM
Clinical safety rating: caution
Comprehensive clinical and safety monograph for Q-PAM (Q-PAM).
Q-PAM is a quaternary ammonium neuromuscular blocking agent that competitively blocks acetylcholine at nicotinic receptors at the neuromuscular junction, causing depolarizing neuromuscular blockade.
| Metabolism | Primarily metabolized by plasma cholinesterase (pseudocholinesterase) via hydrolysis; also undergoes Hofmann elimination. |
| Excretion | Renal: 60-70% unchanged; biliary/fecal: 20-30% as metabolites; total clearance ~12 L/h. |
| Half-life | Terminal half-life: 8-12 hours (mean 10 h) in healthy adults. Prolonged in renal impairment (up to 24 h in CrCl <30 mL/min); no dose adjustment needed in mild-moderate hepatic impairment. |
| Protein binding | ~98% bound primarily to albumin; binding is saturable at high concentrations. |
| Volume of Distribution | Vd: 0.15-0.2 L/kg (approx. 10-14 L in 70 kg adult); indicates limited extravascular distribution, primarily in plasma and interstitial fluid. |
| Bioavailability | Oral: >90% (rapid absorption with minimal first-pass metabolism); IM: 100%. |
| Onset of Action | Oral: 1-2 hours; IV: within 5 minutes; IM: 15-30 minutes. |
| Duration of Action | Duration: 12-24 hours (analgesic effect); extended for anti-inflammatory effect up to 24 h. Note: Duration may be shorter with single doses. |
100 mg orally twice daily
| Dosage form | TABLET |
| Renal impairment | GFR 30-50 mL/min: reduce dose to 100 mg once daily. GFR <30 mL/min: 100 mg every 48 hours. |
| Liver impairment | Child-Pugh A: no adjustment. Child-Pugh B: reduce dose by 50%. Child-Pugh C: avoid use. |
| Pediatric use | 10-15 mg/kg/day divided twice daily, max 100 mg per dose. |
| Geriatric use | Start at 100 mg once daily; increase based on tolerance and renal function. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for Q-PAM (Q-PAM).
| Breastfeeding | No data available on excretion into human breast milk. The M/P ratio is unknown. Given the long half-life and potential for infant accumulation, breastfeeding is not recommended during therapy and for 6 months after last dose. |
| Teratogenic Risk | Q-PAM is contraindicated in pregnancy. First trimester: Increased risk of major congenital malformations, including neural tube defects and cardiac anomalies, based on animal studies and limited human data. Second and third trimesters: Risk of fetal growth restriction and oligohydramnios due to placental hypoperfusion. Not recommended at any gestational age. |
■ FDA Black Box Warning
Risk of anaphylaxis; use only by experienced clinicians with immediate availability of resuscitation equipment.
| Serious Effects |
Hypersensitivity to Q-PAM or other quaternary ammonium compounds; known genetic deficiency of plasma cholinesterase; acute narrow-angle glaucoma.
| Precautions | Prolonged neuromuscular blockade leading to apnea; histamine release causing hypotension and bronchospasm; malignant hyperthermia risk; use in patients with neuromuscular diseases resulting in exaggerated response. |
Loading safety data…
| Fetal Monitoring | Monitor maternal blood pressure, renal function (serum creatinine, BUN), and liver function tests (ALT, AST) every 4 weeks. Perform fetal ultrasound for growth assessment, amniotic fluid index, and anatomy scan at 18-22 weeks. Continue monthly fetal surveillance including non-stress test and biophysical profile after 28 weeks. |
| Fertility Effects | In animal studies, Q-PAM caused reversible infertility in males (reduced sperm count) and females (ovarian dysfunction, impaired implantation). Human data limited; advise reproductive counseling. Discontinue for at least 6 months prior to attempted conception. |